# The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

> **NCT05420012** · PHASE4 · COMPLETED · sponsor: **Josef Stehlik** · enrollment: 26 (actual)

## Conditions studied

- Heart Failure
- Heart Failure With Reduced Ejection Fraction (HFrEF)

## Interventions

- **DRUG:** Vericiguat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05420012
- **Lead sponsor:** Josef Stehlik
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-01
- **Primary completion:** 2024-10-24
- **Final completion:** 2024-10-24
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05420012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05420012, "The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05420012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*